嘉因生物冲刺港交所：核心产品为治疗脊髓性肌萎缩症潜在同类最佳候选产品

Core Viewpoint - Exegenesis Bio Inc. (嘉因生物) is focused on gene therapy and oligonucleotide drugs, with a strong emphasis on innovative delivery systems and a diverse product pipeline aimed at addressing significant unmet clinical needs in both rare and common diseases [2][4]. Company Overview - Exegenesis Bio Inc. was established in 2019 and has developed advanced delivery vector technologies, positioning itself as a leader in the biopharmaceutical industry [2]. - The company has submitted its IPO application to the Hong Kong Stock Exchange, with CCB International acting as the sole sponsor [2]. Product Pipeline - The company’s core candidate product, EXG001-307, is a promising gene therapy for Spinal Muscular Atrophy (SMA) type 1, expected to be a best-in-class treatment [4][5]. - Other key candidates include EXG102-031, targeting wet Age-related Macular Degeneration (wAMD), and EXG202, aimed at treating retinal neovascular diseases, including wAMD and Diabetic Macular Edema (DME) [4][5]. - EXG001-307 is noted for its single-dose administration and its ability to minimize expression in peripheral tissues, addressing safety concerns associated with current gene therapies [4]. Market Potential - The global market for SMA treatments is projected to grow from $4.6401 billion in 2024 to $5.9319 billion by 2030, and further to $9.4469 billion by 2035 [4]. - The market for retinal neovascular disease treatments is estimated to increase from $15.6 billion in 2024 to $29.5 billion by 2030, and to $55.8 billion by 2035 [5]. Investment and Funding - Exegenesis Bio has attracted investments from notable institutions such as Hillhouse Capital, Sequoia, and Temasek, among others [6]. - The net proceeds from the IPO are intended to fund the development of core products EXG001-307, EXG102-031, and EXG202, as well as to enhance technological capabilities and support general corporate purposes [6].